Does Blue Cross Blue Shield of Michigan Cover Lantus?

How BCBSM Formulary Coverage Works for Lantus

Blue Cross Blue Shield of Michigan maintains a tiered formulary system that classifies medications by cost and clinical preference. Lantus (insulin glargine U-100), manufactured by Sanofi, has been a cornerstone of basal insulin therapy since its FDA approval in 2000. Where it lands on a given BCBSM formulary depends on the member's specific plan.

Tier Placement and What It Means for Your Costs

BCBSM uses a multi-tier structure. Tier 1 holds generics and lowest-cost options. Tier 2 is for preferred brands. Tier 3 covers non-preferred brands, and specialty tiers sit above that.

Lantus most commonly appears on Tier 2 (preferred brand) or Tier 3 (non-preferred brand) across BCBSM commercial plans. The distinction matters. A Tier 2 placement could mean a $30 to $50 copay, while Tier 3 may push costs to $75 to $150 per fill. Members should verify their specific formulary through the BCBSM member portal or by calling the number on the back of their insurance card.

Biosimilar Pressure on Brand Lantus

The insulin glargine biosimilar market has shifted formulary dynamics considerably. The FDA has approved multiple biosimilars to Lantus, including Semglee (insulin glargine-yfgn) and Rezvoglar (insulin glargine-aglr). A 2023 analysis in Diabetes Care found that biosimilar insulin glargine products demonstrated comparable glycemic control to brand Lantus, with no clinically meaningful differences in HbA1c reduction or hypoglycemia rates across 52 weeks.

BCBSM may prefer these biosimilars on lower tiers, which can trigger step therapy requirements for brand Lantus. If your plan requires you to try a biosimilar first, your prescriber can submit a formulary exception request if there is a clinical reason you need brand Lantus specifically.

Michigan's Insulin Copay Cap Law

Michigan enacted Public Act 185 in 2020, creating one of the strongest insulin affordability protections in the country. The law caps out-of-pocket costs for insulin at $50 per 30-day supply for state-regulated commercial insurance plans.

Who Qualifies for the $50 Cap

The cap applies to Michigan-regulated individual and group health plans. Self-funded employer plans (governed by federal ERISA law rather than state insurance regulation) are not required to comply, though some voluntarily adopt similar limits. BCBSM administers both fully insured and self-funded plans, so members need to confirm which type they have.

How the Cap Interacts with Your Deductible

Under Public Act 185, the $50 cap applies regardless of whether the member has met their annual deductible. This is a significant benefit for members on high-deductible health plans (HDHPs) who might otherwise face the full retail price of Lantus early in the plan year. The average wholesale price of Lantus hovers near $350 per vial and approximately $550 per box of five KwikPens, making the cap a meaningful cost reduction for most members.

Prior Authorization and Step Therapy Requirements

Not every BCBSM plan requires prior authorization for Lantus, but the requirements vary enough that members should check before filling a prescription.

When Prior Authorization Applies

For members with type 1 diabetes, Lantus rarely requires prior authorization because basal insulin is considered first-line therapy. The American Diabetes Association's Standards of Care (2024) recommends insulin as the initial pharmacotherapy for all patients with type 1 diabetes, making utilization management barriers uncommon.

For type 2 diabetes, the picture is more complex. Some BCBSM plans position biosimilar insulin glargine as the preferred first step. Members prescribed brand Lantus may need their provider to document that they tried a biosimilar without adequate response, or that a clinical contraindication exists.

How to Manage a Denial

If BCBSM denies coverage or places Lantus at a higher tier than expected, members have several options. The prescriber can submit a prior authorization or formulary exception request, typically requiring documentation of medical necessity. BCBSM must respond to standard prior authorization requests within 72 hours and urgent requests within 24 hours under Michigan insurance regulations.

An internal or external appeal can be filed if the initial request is denied. According to CMS guidelines, approximately 40% to 60% of initial insulin coverage denials are overturned on appeal when adequate clinical documentation is submitted.

Cost Comparison: Lantus vs. Biosimilar Insulin Glargine on BCBSM

Understanding the price difference between Lantus and its biosimilars can help members make informed decisions about which product to use.

Retail Price Differences

Brand Lantus carries a list price of roughly $340 per vial (10 mL, 100 units/mL). Semglee, the first interchangeable biosimilar insulin glargine, launched with a list price approximately 65% lower than brand Lantus. A 2022 study published in JAMA Internal Medicine documented that biosimilar insulin adoption could save the U.S. Healthcare system an estimated $1.2 billion annually if biosimilar prescribing reached 80% market share.

Clinical Equivalence Data

The INSTRIDE trials established biosimilar equivalence for insulin glargine-yfgn (Semglee). In the INSTRIDE 1 trial (N=558), patients with type 1 diabetes achieved equivalent HbA1c reductions at 52 weeks (mean difference 0.07%, 95% CI: -0.12 to 0.26), confirming therapeutic equivalence within predefined margins.

For most BCBSM members, switching from Lantus to a biosimilar glargine will not produce a detectable change in blood glucose control. The American Diabetes Association's 2024 Standards of Care states that "biosimilar insulins may be a lower-cost alternative to branded insulin products with similar efficacy and safety profiles."

When Staying on Brand Lantus Makes Sense

Some patients experience anxiety around switching insulin products, and others report subjective differences in injection-site comfort or pen device ergonomics. If a member has been stable on brand Lantus for years and their glycemic control is optimal (HbA1c at or below their individualized target), the prescriber may request a formulary exception to keep the member on brand Lantus at a preferred tier copay.

BCBSM Medicare Advantage and Lantus Coverage

Medicare Advantage plans administered by BCBSM follow different formulary rules than commercial plans.

The $35 Insulin Cap Under the Inflation Reduction Act

The Inflation Reduction Act of 2022 capped insulin copays at $35 per month for Medicare Part D beneficiaries, effective January 2023. This federal cap applies to all covered insulin products, including Lantus. A Kaiser Family Foundation analysis estimated that roughly 1.5 million Medicare Part D enrollees who use insulin saved an average of $500 per year under this cap.

Formulary Differences Between Commercial and Medicare Plans

BCBSM Medicare Advantage formularies may place Lantus on different tiers than commercial formularies. Medicare plans also use a coverage gap (formerly the "donut hole"), though the Inflation Reduction Act eliminated out-of-pocket costs in the catastrophic phase and capped total annual Part D out-of-pocket spending at $2,000 starting in 2025. For Lantus users, this means predictable costs throughout the year regardless of tier placement.

How to Verify Your Specific BCBSM Lantus Coverage

Formularies change annually (and sometimes mid-year). A few concrete steps can confirm exactly what your plan covers.

Step-by-Step Verification Process

First, log in to the BCBSM member portal at bcbsm.com and manage to the prescription drug benefits section. Enter "insulin glargine" or "Lantus" in the formulary search tool. The result will show tier placement, any quantity limits, and whether prior authorization or step therapy applies.

Second, call BCBSM member services using the phone number on your insurance card. Ask specifically: "Is Lantus on my formulary, what tier is it on, and are there any utilization management requirements?" Request a reference number for the call.

Third, ask your pharmacist to run a test claim. This generates a real-time adjudication that shows the exact copay or coinsurance amount your plan would charge at that moment.

What to Do If Lantus Is Not Covered

If your specific BCBSM plan excludes Lantus entirely (rare but possible with some narrow formulary designs), your prescriber can submit an exception request. Alternatively, switching to a covered biosimilar glargine product may be the fastest path to affordable basal insulin.

Manufacturer and Community Assistance Programs

Even with insurance coverage, some BCBSM members may face affordability challenges. Several programs can reduce costs further.

Sanofi Patient Assistance

Sanofi operates the Insulins ValYou Savings Program for patients without insurance or with commercial insurance that does not cover Lantus. Eligible patients pay $35 per month for up to 10 boxes of Lantus pens or 10 vials. The program does not apply to government-funded insurance (Medicare, Medicaid, TRICARE).

Michigan-Specific Resources

The Michigan Department of Health and Human Services maintains an insulin assistance directory. The CDC's National Diabetes Prevention Program also operates recognized sites throughout Michigan that can connect residents with prescription assistance resources.

340B Drug Pricing

Patients who receive care at 340B-eligible health centers (including many Federally Qualified Health Centers in Michigan) may access Lantus at significantly reduced prices. A Health Affairs analysis found that 340B contract pharmacies dispensed insulin at 25% to 50% below average commercial prices.

Clinical Context: Why Basal Insulin Coverage Matters

Lantus and its biosimilars are not optional medications for the patients who need them. Basal insulin is the pharmacologic backbone of type 1 diabetes management and a common component of type 2 diabetes regimens when oral agents and GLP-1 receptor agonists are insufficient.

The Consequences of Insulin Rationing

A 2019 study in JAMA Internal Medicine (N=1,500) found that one in four insulin-dependent patients reported cost-related insulin underuse, including skipping doses, taking less than prescribed, or delaying refills. Among those who rationed, mean HbA1c was 0.62 percentage points higher than among those who did not, a clinically significant difference associated with increased long-term complication risk.

Glycemic Targets and Lantus Efficacy

The ORIGIN trial (N=12,537), published in the New England Journal of Medicine, demonstrated that insulin glargine maintained median HbA1c at 6.2% over 6.2 years of follow-up in patients with early type 2 diabetes or prediabetes. The trial also confirmed a neutral cardiovascular safety profile, with no increased risk of major adverse cardiovascular events (HR 1.02, 95% CI: 0.94 to 1.11).

Patients starting Lantus typically begin at 10 units daily (or 0.2 units/kg/day) and titrate by 2 to 4 units every 3 to 7 days until fasting blood glucose reaches the target range of 80 to 130 mg/dL, per ADA recommendations.